TABLE OF CONTENTS
Volume 6, Issue 2 (March/April 2006)
In This Issue
Top of pageMeeting Reports
Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop
R A Salerno and L J Lesko
Pharmacogenomics J 6: 78-81; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500345
Retrospective validation of genomic biomarkers – what are the questions, challenges and strategies for developing useful relationships to clinical outcomes – workshop summary
S-J Wang, N Cohen, D A Katz, G Ruano, P M Shaw and B Spear
Pharmacogenomics J 6: 82-88; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500363
Designing prospective clinical pharmacogenomic (PG) trials: meeting report on drug development strategies to enhance therapeutic decision making
W L Trepicchio, D Essayan, S T Hall, G Schechter, Z Tezak, S J Wang, D Weinreich and R Simon
Pharmacogenomics J 6: 89-94; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500344
Review
Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease
F Fumagalli, G Racagni and M A Riva
Pharmacogenomics J 6: 95-104; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500360
Original Articles
Sequence diversity and haplotype structure at the human CYP3A cluster
E E Thompson, H Kuttab-Boulos, L Yang, B A Roe and A Di Rienzo
Pharmacogenomics J 6: 105-114; advance online publication, November 29, 2005; doi:10.1038/sj.tpj.6500347
CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation
T Kubota, C Nakajima-Taniguchi, T Fukuda, M Funamoto, M Maeda, E Tange, R Ueki, K Kawashima, H Hara, Y Fujio and J Azuma
Pharmacogenomics J 6: 115-119; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500348
Apolipoprotein D is associated with long-term outcome in patients with schizophrenia
T Hansen, R P Hemmingsen, A G Wang, L Olsen, S Timm, K Søeby, K D Jakobsen, M Fenger, J Parnas, H B Rasmussen and T Werge
Pharmacogenomics J 6: 120-125; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500350
(AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population
N Ballon, S Leroy, C Roy, M C Bourdel, A Charles-Nicolas, M O Krebs and M F Poirier
Pharmacogenomics J 6: 126-130; advance online publication, November 29, 2005; doi:10.1038/sj.tpj.6500352
cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects
S Sondhi, J M Castellano, V Z Chong, R M Rogoza, K J Skoblenick, B A Dyck, J Gabriele, N Thomas, K Ki, Z B Pristupa, A N Singh, D MacCrimmon, P Voruganti, J Foster and R K Mishra
Pharmacogenomics J 6: 131-140; advance online publication, December 13, 2005; doi:10.1038/sj.tpj.6500346
Gene expression analysis in a murine model of allergic asthma reveals overlapping disease and therapy dependent pathways in the lung
M T Follettie, D K Ellis, D D Donaldson, A A Hill, V Diesl, C DeClercq, J P Sypek, A J Dorner and M Wills-Karp
Pharmacogenomics J 6: 141-152; advance online publication, January 10, 2006; doi:10.1038/sj.tpj.6500357
